Who Paid My Doc
Gregory Lundeen
Foot and Ankle Surgery Reno, NV Medical Doctor
NPI 1720036270 CMS profile 214274
555 N Arlington Ave, Reno, NV 89503
General payments
$301,436
Research payments
$0
Ownership & investment interest
$132,750
Research they led as principal investigator
$217,376
Through program year 2025, Gregory Lundeen of Reno, NV is reported in the CMS Open Payments database as having received $301,436 across 368 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $217,376 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $132,750 across 4 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $48,604 | 73 | |
| 2024 | General | $51,984 | 47 | |
| 2023 | General | $10,935 | 30 | |
| 2022 | General | $58,519 | 58 | |
| 2021 | General | $50,091 | 74 | |
| 2020 | General | $52,503 | 37 | |
| 2019 | General | $28,801 | 49 | |
| 2022 | Ownership | $35,000 | 1 | |
| 2021 | Ownership | $34,000 | 1 | |
| 2020 | Ownership | $32,500 | 1 | |
| 2019 | Ownership | $31,250 | 1 |
Beside peers
- Gregory Lundeen
- Foot and Ankle Surgery median
- Middle half of Foot and Ankle Surgery
- National median
In program year 2025, general payments to Gregory Lundeen were reported at $48,604. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.
Show as a table
| Year | Gregory Lundeen | Foot and Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $28,801 | $1,327 | $279–$5,421 | $163 |
| 2020 | $52,503 | $795 | $121–$3,473 | $114 |
| 2021 | $50,091 | $1,289 | $201–$4,963 | $132 |
| 2022 | $58,519 | $1,539 | $270–$6,067 | $149 |
| 2023 | $10,935 | $1,117 | $257–$5,264 | $160 |
| 2024 | $51,984 | $1,064 | $235–$4,944 | $164 |
| 2025 | $48,604 | $1,183 | $267–$6,309 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
823
Drug cost
$4,077
Branded share of claims
10.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycodone Hcl | Generic | 240 | $1,283 | |
| Gabapentin | Generic | 256 | $1,176 | |
| Hydroxyzine Pamoate | Generic | 179 | $658 | |
| Pregabalin | Generic | 18 | $441 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 43 | $227 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 13 | $146 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 27 | $70 | |
| Cephalexin | Generic | 14 | $50 | |
| Meloxicam | Generic | 18 | $14 | |
| Amoxicillin | Generic | 15 | $11 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 142 billing codesPaid by Medicare
$215,493
Medicare patients
393
Services billed
1,883
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 73% | |
| High blood pressure | 64% | |
| Depression | 18% | |
| Osteoporosis | 17% | |
| Diabetes | 16% | |
| Ischemic heart disease | 16% | |
| Chronic kidney disease | 15% | |
| Atrial fibrillation | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 42 | 54 | $284 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
368 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Foot and Ankle Surgery in Nevada
Troy Watson
Foot and Ankle Surgery · Las Vegas, NV
Roman Sibel
Foot and Ankle Surgery · Henderson, NV
Abdolreza Raissi
Foot and Ankle Surgery · Las Vegas, NV
Holman Chan
Foot and Ankle Surgery · Henderson, NV
Scott Whitlow
Foot and Ankle Surgery · Reno, NV
Paul Ryan
Foot and Ankle Surgery · Carson City, NV
Related records
Foot and Ankle Surgery in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Foot and Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.